Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CAO Sells 839 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CAO Robert F. Werner sold 839 shares of Twist Bioscience stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $27.73, for a total value of $23,265.47. Following the completion of the sale, the chief accounting officer now directly owns 50,191 shares of the company's stock, valued at $1,391,796.43. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Twist Bioscience Trading Up 6.0%

NASDAQ:TWST traded up $1.77 on Monday, reaching $31.07. The company's stock had a trading volume of 1,908,700 shares, compared to its average volume of 984,617. Twist Bioscience Co. has a 1-year low of $27.12 and a 1-year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The firm has a market cap of $1.86 billion, a PE ratio of -9.19 and a beta of 2.54. The business's 50-day moving average price is $35.28 and its two-hundred day moving average price is $42.29.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on TWST shares. The Goldman Sachs Group decreased their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird decreased their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays decreased their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently modified their holdings of TWST. Versant Capital Management Inc lifted its holdings in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares in the last quarter. Van ECK Associates Corp lifted its holdings in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Twist Bioscience in the fourth quarter valued at about $43,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the fourth quarter valued at about $58,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.